Literature DB >> 34709105

Meta-analysis of prevalence: the psychological sequelae among COVID-19 survivors.

Bann Khraisat1, Ahmad Toubasi1, Lujain AlZoubi1, Thuraya Al-Sayegh1, Ahmad Mansour2.   

Abstract

OBJECTIVE: This meta-analysis aims to estimate the pooled prevalence of mental disorders among COVID-19 survivors.
METHODS: The databases Pubmed, Google Scholar, ScienceDirect, and medRxiv have been searched up to 1 August 2021 using COVID-19, survivors, mental disorders, and their related MeSH terms. The included studies were either cross-sectional, cohort, or case-control in design. Those studies included COVID-19 survivors after 14 or more days from their COVID-19 recovery and used validated questionnaires to assess their mental health outcomes. The random-effects model was used to pool the data from the incorporated studies. The heterogeneity was assessed using Cochran's Q heterogeneity test and I2 statistic.
RESULTS: Twenty-seven studies were included in the data synthesis with a total sample size of 9605 COVID-19 survivors. The prevalence rates for Post-Traumatic Stress Disorder (PTSD), anxiety, psychological distress, depression, and sleeping disorders were 20% (95% CI = 16-24%), 22% (95% CI = 18-27%), 36% (95% CI = 22-51%), 21% (95% CI = 16-28%), and 35% (95% CI = 29-41%), respectively.
CONCLUSIONS: Although we found high heterogeneity across the included studies, our meta-analysis provides evidence that there are psychological sequelae in COVID-19 survivors that require medical assiduity as well as further research on the matter.KEY POINTSIncreased prevalence of psychological sequelae among COVID-19 survivors.The prevalence of PTSD was 20% (95% CI = 16-24%) and of anxiety was 22% (95% CI = 18-27%) among COVID-19 survivors.The prevalence of psychological distress was 36% (95% CI = 22-51%), of depression was 21% (95% CI = 16-28%), and of sleep disorders was 35% (95% CI = 29-41%) among COVID-19 survivors.Future researches are recommended to search for effective and safe methods to mitigate the psychological sequelae in COVID-19 patients.

Entities:  

Keywords:  COVID-19; Humans; meta-analysis; psychological distress; survivors

Mesh:

Year:  2021        PMID: 34709105     DOI: 10.1080/13651501.2021.1993924

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   2.750


  5 in total

1.  Anxiety, Stress and Depression in COVID-19 Survivors From an Italian Cohort of Hospitalized Patients: Results From a 1-Year Follow-Up.

Authors:  Carla Gramaglia; Eleonora Gattoni; Eleonora Gambaro; Mattia Bellan; Piero Emilio Balbo; Alessio Baricich; Pier Paolo Sainaghi; Mario Pirisi; Valeria Binda; Alessandro Feggi; Amalia Jona; Debora Marangon; Pierluigi Prosperini; Patrizia Zeppegno
Journal:  Front Psychiatry       Date:  2022-06-17       Impact factor: 5.435

2.  Post-traumatic stress disorder, anxiety, depression and related factors among COVID-19 patients during the fourth wave of the pandemic in Vietnam.

Authors:  Hoang Bac Nguyen; Thi Hong Minh Nguyen; Thi Hong Nhan Vo; Thi Cam Nhung Vo; Duc Nguyet Quynh Nguyen; Huu-Thinh Nguyen; Tuan-Ngan Tang; Thi-Hiep Nguyen; Van Trang Do; Quang Binh Truong
Journal:  Int Health       Date:  2022-06-13       Impact factor: 3.131

3.  The Moderating Effect of Resilience on Mental Health Deterioration among COVID-19 Survivors in a Mexican Sample.

Authors:  Héctor Raúl Pérez-Gómez; Esteban González-Díaz; Marta Herrero; Fabiola de Santos-Ávila; José Luis Vázquez-Castellanos; Pedro Juárez-Rodríguez; Bernardo Moreno-Jiménez; Rosa Martha Meda-Lara
Journal:  Healthcare (Basel)       Date:  2022-02-05

4.  Long COVID: the elephant in the room.

Authors:  B D Kelly; G Gulati
Journal:  QJM       Date:  2022-01-21

5.  New symptoms and prevalence of postacute COVID-19 syndrome among nonhospitalized COVID-19 survivors.

Authors:  Asma S Albtoosh; Ahmad A Toubasi; Khaled Al Oweidat; Manar M Hasuneh; Abdullah H Alshurafa; Daniah L Alfaqheri; Randa I Farah
Journal:  Sci Rep       Date:  2022-10-08       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.